Glenmark in licensing deal with Sanofi

Glenmark Pharmaceuticals signed a  licensing agreement   with Sanofi  where the prior company is  expected to receive  USD 613 million  in addition to  royalties on sales  for the   molecule - GBR500 which is  used  for treatment of Crohn's disease .

 Under the deal, Sanofi will have exclusive marketing rights for North America, Europe, Japan, Argentina, China and Uruguay  while   both the companies would co-market in Russia, Brazil, Australia and New Zealand. 
Glenmark will retain exclusive marketing rights in India and other countries in the rest of the world.